Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions
The DOI matches its OpenAlex record.
Abstract
Vasoactive intestinal polypeptide (VIP) has a variety of physiological effects. Pharmacological evidence suggesting that VIP acts via multiple receptors has been confirmed by the cloning of two VIP receptors (VIP1 and VIP2) with very different amino acid sequences. At both the VIP1 and the VIP2 receptor VIP, PHI, PACAP38, and PACAP27 have similar potency to each other. Only the VIP1 receptor is activated by secretin. The messenger RNAs (mRNAs) for the two receptors have completely different distributions as mapped by in situ hybridization histochemistry. VIP1 receptor mRNA is predominantly found in the lung, small intestine, thymus, and within the brain in the cerebral cortex and hippocampus. VIP2 receptor mRNA is present in a number of areas where VIP acts but VIP1 receptor mRNA is not present, including the stomach and testes. In the CNS VIP2 receptor mRNA is exclusively present in areas associated with neuroendocrine function, including several hypothalamic nuclei. In the periphery, it is also present in the pituitary and in pancreatic islets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions
Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., Fournier, A., & Vaudry, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01449-2 · Cited by 1,121
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K. C., Hashimoto, H., Galas, L., et al. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001370 · Cited by 1,058
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Neuronal Control of Skin Function: The Skin as a Neuroimmunoendocrine Organ
Roosterman, D., Goerge, T., Schneider, S. W., Bunnett, N. W., & Steinhoff, M. (2006) · Physiological Reviews · doi:10.1152/physrev.00026.2005 · Cited by 665
ARIMURA, A. (1998) · The Japanese Journal of Physiology · doi:10.2170/jjphysiol.48.301 · Cited by 512
Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., Vaudry, D., Vaudry, H., Waschek, J. A., & Said, S. I. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01871.x · Cited by 471
Usdin, T. B., Gruber, C., & Bonner, T. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.26.15455 · Cited by 422
Self-citationThe Significance of Vasoactive Intestinal Peptide in Immunomodulation
Delgado, M., Pozo, D., & Ganea, D. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.7 · Cited by 412
Disrupted circadian rhythms in VIP- and PHI-deficient mice
Colwell, C. S., Michel, S., Itri, J., Rodriguez, W., Tam, J., Lelievre, V., Hu, Z., Liu, X., & Waschek, J. A. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00200.2003 · Cited by 392
VPAC and PAC receptors: From ligands to function
Dickson, L., & Finlayson, K. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.006 · Cited by 379
Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T., Sakaue, M., Miyazaki, J.-I., Niwa, H., Tashiro, F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231094498 · Cited by 373
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G.-C., Hamilton, G., Novotny, C., Burian, B., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17500 · Cited by 352
PDF Receptor Signaling in Drosophila Contributes to Both Circadian and Geotactic Behaviors
Mertens, I., Vandingenen, A., Johnson, E. C., Shafer, O. T., Li, W., Trigg, J. S., De Loof, A., Schoofs, L., & Taghert, P. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.009 · Cited by 332
RAWLINGS, S. R., & HEZAREH, M. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-1-4 · Cited by 315
Hannibal, J., Ding, J. M., Chen, D., Fahrenkrug, J., Larsen, P. J., Gillette, M. U., & Mikkelsen, J. D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02637.1997 · Cited by 288
Vasoactive intestinal peptide: cardiovascular effects
Henning, R. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00229-7 · Cited by 280
Neurotransmitters of the retino-hypothalamic tract
Hannibal, J. (2002) · Cell and Tissue Research · doi:10.1007/s00441-002-0574-3 · Cited by 276
Olsson, C., & Holmgren, S. (2001) · Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology · doi:10.1016/s1095-6433(00)00330-5 · Cited by 262
Neuropeptides and hippocampal neurogenesis
Zaben, M. J., & Gray, W. P. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.002 · Cited by 75
Select cognitive deficits in vasoactive intestinal peptide deficient mice
Chaudhury, D., Loh, D. H., Dragich, J. M., Hagopian, A., & Colwell, C. S. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-63 · Cited by 73
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
Fahrenkrug, J., Georg, B., Hannibal, J., & Jørgensen, H. L. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9804-7 · Cited by 27
Metadata
- Authors
- Usdin, T. B.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1994-12
- Volume
- 135
- Issue
- 6
- Pages
- 2662-2680
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W4236558664
- Cited by
- 427
- References
- 0
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.